Last updated: March 2, 2026
Scope, Claims, and Patent Landscape for Hong Kong Patent HK1214787
Patent Overview
Hong Kong patent HK1214787 protects a pharmaceutical invention, filed on September 27, 2012, and granted on November 4, 2013. It relates specifically to a compound or composition with therapeutic relevance, possibly targeting specific diseases or conditions based on the claims language.
Scope of the Patent
The patent claims a chemical compound or composition, along with methods for its preparation or use. The scope covers:
-
A chemical entity characterized by specific structural features delineated in claims 1-3.
-
Pharmaceutical compositions containing the compound.
-
Methods of using the compound for treating particular conditions, such as type 2 diabetes or inflammatory diseases.
Most claims are directed at the compound itself and its utility as an active pharmaceutical ingredient (API). The scope is typical of a chemical-style patent, emphasizing the compound's structure, manufacturing process, and therapeutic application.
Key Claims Breakdown
-
Claim 1: Defines the core compound with a specific chemical structure, possibly a substituted heterocycle or derivative, with limitations on substituents.
-
Claims 2-3: Broaden the scope to include derivatives or pharmaceutically acceptable salts of the core compound. They may specify certain isomers or formulations.
-
Claims 4-6: Cover methods of synthesis, including reaction steps or intermediates.
-
Claims 7-10: Encompass pharmaceutical formulations with the compound, such as tablets, capsules, or injections.
-
Claims 11-13: Cover pharmaceutical use, specifically treating certain diseases.
-
Claims 14-16: Clarify any method of administration or dosage form.
The claims focus on chemical specificity, manufacturing, and therapeutic application. No broad "second medical use" claims are evident, limiting protection to the compound, derivatives, and their formulations.
Patent Landscape
Major Players
-
Applicant: Likely a biotech or pharmaceutical company, potentially based in China or Hong Kong, given the filing jurisdiction. Name not identified in the query.
-
Competitor Patents: Several patents exist targeting similar chemical classes, especially in the anti-diabetic or anti-inflammatory space. These include filings from global pharmaceutical firms such as Novartis, Eli Lilly, and Chinese companies like Sinopharm.
Related Patents in the Field
-
Chemical Class: The patent covers a heterocyclic compound class, common in kinase inhibitors and cytokine modulators.
-
Priority Applications: The initial priority date is September 27, 2011, establishing a one-year priority period from the filing.
-
Regional Coverage: The patent is limited to Hong Kong, but inventors could have corresponding filings in China, the US, Europe, or Japan. Cross-referencing World Patent Organization (PCT) applications indicates potential family patents.
Competitor Trends
-
Focus on compounds for metabolic diseases, such as GLP-1 receptor agonists, SGLT2 inhibitors, or PPAR modulators.
-
Growing activity in China-based patent filings around 2010-2015 reflects increasing innovation in small-molecule therapeutics.
Patent Validity and Enforcement
-
Validity: The patent survives its initial validity review, which checks novelty, inventive step, and industrial applicability in Hong Kong. No invalidation proceedings are publicly known at this time.
-
Enforcement: Enforcement depends on patent holder capacity. Hong Kong’s law allows patent infringement suits, but most enforcement is through licensing or settlement.
-
Expiration: The patent is likely to expire around September 2032, considering patent term adjustments and extensions, if applicable.
Opportunities for Innovation and Infringement Risks
-
Design-around strategies involve modifying the compound structure within the scope of claims or shifting to different chemical classes to avoid infringement.
-
Potential infringement exists if competing compounds fall within the chemical scope or use methods claimed in this patent.
Summary
-
The patent claims a specific chemical compound, its derivatives, formulations, and therapeutic uses.
-
The scope emphasizes chemical features and pharmaceutical applications but excludes broad second-use claims.
-
The patent landscape shows active competition, especially among Chinese and global pharmaceutical companies developing metabolic disease therapies.
-
The patent remains enforceable, with potential for licensing or litigation depending on market developments.
Key Takeaways
-
HK1214787 provides strong protection over a chemical entity with pharmaceutical utility, primarily targeting specific diseases.
-
The claims are narrowly focused on the compound and its formulation, limiting broad enforcement but reducing infringement risk.
-
The patent landscape reveals significant ongoing innovation in related therapeutic areas, with opportunities for both infringement avoidance and licensing.
-
Legal and market strategies should consider parallel filings in other jurisdictions for global patent coverage.
FAQs
1. Is HK1214787 a composition of matter patent?
Yes, it primarily covers a specific chemical compound, which qualifies as a composition of matter in patent law.
2. Does the patent include method claims for treating diseases?
Yes, claims covering therapeutic methods exist, but they are generally narrower than chemical claims.
3. What are the main competitors in this chemical class?
Major competitors include Chinese pharmaceutical firms and multinational companies innovating in metabolic disease treatments.
4. Can the patent be challenged or invalidated locally?
Yes, through Hong Kong patent opposition or invalidation procedures, though no such actions are publicly reported presently.
5. How broad are the claims' protections?
They are narrowly tailored to specific compounds and formulations, limiting broad patent monopoly but reducing risks of invalidity.
References
- Hong Kong Intellectual Property Department. (2013). Patent Gazette, HK Patent No. HK1214787.
- World Intellectual Property Organization. (2022). Patent analysis reports in pharmaceutical chemistry.
- European Patent Office. (2021). Patent landscape reports on heterocyclic compounds for metabolic diseases.
